Biocardia announces fda clearance for morph dna deflectable guide catheter

San carlos, calif., jan. 14, 2020 (globe newswire) -- biocardia®, inc.  [otc: bcda], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the u.s. food and drug administration (fda) has granted 510(k) clearance for the morph® dna deflectable guide catheter used to guide the helix™ biotherapeutic delivery system during cardiamp™ cell therapy delivery in the heart.
BCDA Ratings Summary
BCDA Quant Ranking